Short-term choroidal thickness changes in patients treated with either ranibizumab or aflibercept: a comparative study

Abstract

A greater decrease in choroidal thickness was noted in eyes treated with aflibercept than in eyes treated with ranibizumab. This difference was more marked in PCV than in other subtypes of neovascular AMD.